Clinical effects of neoafjuvant chemotherapy in stage IIIA non-small cell lung cancer.
- Author:
Seong Su JEONG
1
;
Dong Won KANG
;
Gyu Seung LEE
;
Dong Seok KO
;
Jae Chul SUH
;
Geun Hwa KIM
;
Ju Ock KIM
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, Chungnam National University, Taejon, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Neoadjuvant chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin;
Drug Therapy*;
Humans;
Korea;
Lung;
Male;
Neoadjuvant Therapy;
Recurrence
- From:Korean Journal of Medicine
1999;57(2):183-190
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Surgical therapy remains the only curative treatment of localized non-small cell lung cancer(NSCLC). But the efficacy of surgery for patients with NSCLC is limited, although recent studies suggest that neoadjuvant chemotherapy may improve survival. Many studies also demonstrated benefit for neoadjuvant therapy. However very few studies about neoadjuvant chemotherapy were reported in Korea. We conducted this study to examine the possible benefit of neoadjuvant chemotherapy in patients with operable stage IIIA NSCLC. METHODS: Twenty seven patients(25 men and 2 women) with clinical stage IIIA NSCLC were analyzed. The patients received 2 to 4 courses of cisplatin based chemotherapy and followed by surgery. To compare the resection rate and survival, 12 patients(10 men, 2 women) with clinical stage IIIA and initially treated operation were also anayzed. RESULTS: The radiologically assessed response rate to the neoadjuvant therapy was 59.3%. Twelve seven patients underwent gross tumor resection with 24(88.9%) having complete resection and 21(77.8%) having postaperative stage I ar II. Pathologically defined response in nodal staging was more higher(85.2%). There was no difference of relapse free interval in recurred patients between two groups. But in patients treated with neoadjuvant therapy, distant recurrence is less higher than local recurrence. The median period of survival was 42 months in the patients treated with neoadjuvant therapy, and 27 months in the patients initially treated with surgery(p=0.287). CONCLUSION: The neoadjuvant chemotherapy improves local tumor control and lowers the distant recurrence. There was a possible trend improving median survival. So neoadjuvant chemotherapy might be considered as a standard therapy in stage IIIA NSCLC.
